BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
36.85
+0.10 (0.27%)
At close: Feb 26, 2026
9.84%
Market Cap 4.58B
Revenue (ttm) 222.34M
Net Income (ttm) -84.61M
Shares Out 124.36M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 296,175
Average Volume 214,327
Open 36.70
Previous Close 36.75
Day's Range 36.20 - 37.20
52-Week Range 23.20 - 49.15
Beta 0.19
RSI 46.21
Earnings Date Feb 26, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Financial Statements

News

There is no news available yet.